Future Growth PotentialThe anticipated mid-2025 commercial launch of the new Catamaran SE device could serve as a meaningful growth driver.
Market OpportunityWith a significant market opportunity and superior technology, TNON is considered undervalued, supporting a Buy rating.
Regulatory ApprovalTNON's Catamaran SI Joint Fusion System received an expanded indication from the FDA for use in augmenting thoracolumbar fusion, significantly increasing the company’s total addressable market.